Sodium glucose co-transporter 2 (SGLT2) inhibitor use in patients with heart failure with preserved ejection fraction (HFpEF) has generated great enthusiasm, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
The data on using sodium glucose co-transporter 2 (SGLT2) inhibitors in patients with heart failure with preserved ejection fraction (HFpEF) have generated great enthusiasm, although we still don't quite know how to explain all of the salutary effects, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
De Boer presented “HFpEF Management: State of the Art SGLT2 Inhibitors” today at ESC Congress 2021, this year’s virtual annual meeting of the European Society of Cardiology.
Transcript
What did your presentation on SGLT2 inhibitors in HFpEF address?
There's been ample interest for the use of SGLT2 inhibitors in heart failure with preserved ejection fraction, and that mainly has to do with the fact that, during this ESC, the EMPEROR-Preserved trial was presented, which is the first morbidity/mortality trial in HFpEF with an SGLT2 inhibitor. The primary end point was effectively reduced by the use of the SGLT2 inhibitors. So that clearly sparks enthusiasm and has attracted a lot of interest.
My talk dealt with the aggregate evidence that has been obtained for SGLT2 inhibition in heart failure with preserved ejection fraction. And clearly before this trial was presented, there were already quite a few signals from other trials, post hoc analyses, some smaller-scale trials, that these drugs, indeed, could be efficacious with regards to reducing end points.
I discussed a series of those studies. There were a few large field trials in the past in type 2 diabetes patients—most notably EMPA-REG, CANVAS, DECLARE-TIMI, and the VERTIS trials—that clearly send signals for a potentially beneficial effect in HFpEF. We've seen quite recently the SOLOIST and the SCORED trials that were presented during the American Heart Association in 2020 and in post hoc analyses of these trials. The patients with HFpEF fared well when allocated to SGLT2 inhibitors.
There were a few smaller trials, and I also discussed some of the potential working mechanisms that might underlie the beneficial effects. To summarize that, I think as it stands now, we still don't know which of the effects of the SGLT2 inhibitors explain all of the salutary effects. But clearly they're very pleiotropic drugs with a number of effects, and clearly, in combination, these effects exert very beneficial effects. So that was, in a nutshell, what I discussed.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More